Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer

NCT07637513 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

430

Enrollment

OTHER

Sponsor class

Conditions

Limited Stage Small-Cell Lung Cancer

Interventions

DRUG: Tarlatamab
DRUG: Durvalumab

Sponsor

PrECOG, LLC.

Collaborators

[object Object]